Johannes Jacob Piete Kastelein Sells 6,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the transaction, the insider owned 73,481 shares in the company, valued at $2,443,243.25. This trade represents a 7.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock traded up $1.43 during midday trading on Wednesday, hitting $35.45. The company had a trading volume of 759,782 shares, compared to its average volume of 845,920. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of -17.29 and a beta of 0.07. The company’s 50 day simple moving average is $36.87 and its 200 day simple moving average is $29.80. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $4.54 million. Analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. purchased a new stake in shares of NewAmsterdam Pharma in the third quarter valued at about $886,000. Polar Capital Holdings Plc raised its holdings in shares of NewAmsterdam Pharma by 15.6% in the third quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after acquiring an additional 393,855 shares during the last quarter. HighVista Strategies LLC increased its position in NewAmsterdam Pharma by 65.1% during the 3rd quarter. HighVista Strategies LLC now owns 31,831 shares of the company’s stock worth $905,000 after purchasing an additional 12,557 shares in the last quarter. Fred Alger Management LLC lifted its stake in shares of NewAmsterdam Pharma by 87.2% during the third quarter. Fred Alger Management LLC now owns 41,264 shares of the company’s stock valued at $1,174,000 after buying an additional 19,227 shares during the period. Finally, Duquesne Family Office LLC boosted its stake in NewAmsterdam Pharma by 131.2% in the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after buying an additional 1,091,525 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NAMS. Stifel Nicolaus boosted their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Citigroup boosted their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Needham & Company LLC raised their price target on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Royal Bank Of Canada upped their price objective on NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.73.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.